JP2019515908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515908A5 JP2019515908A5 JP2018554585A JP2018554585A JP2019515908A5 JP 2019515908 A5 JP2019515908 A5 JP 2019515908A5 JP 2018554585 A JP2018554585 A JP 2018554585A JP 2018554585 A JP2018554585 A JP 2018554585A JP 2019515908 A5 JP2019515908 A5 JP 2019515908A5
- Authority
- JP
- Japan
- Prior art keywords
- independently hydrogen
- compound
- group
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 229940000425 combination drug Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000009118 salvage therapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C*C(C(C(C1C(C)O)O)O)OC1C(O)=O Chemical compound C*C(C(C(C1C(C)O)O)O)OC1C(O)=O 0.000 description 3
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021140920A JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2023179367A JP2024020212A (ja) | 2016-04-20 | 2023-10-18 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
| JP2025134679A JP2025163273A (ja) | 2016-04-20 | 2025-08-13 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325200P | 2016-04-20 | 2016-04-20 | |
| US62/325,200 | 2016-04-20 | ||
| PCT/US2017/028646 WO2017184871A1 (en) | 2016-04-20 | 2017-04-20 | Carbidopa and l-dopa prodrugs and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021140920A Division JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515908A JP2019515908A (ja) | 2019-06-13 |
| JP2019515908A5 true JP2019515908A5 (enExample) | 2020-06-18 |
Family
ID=58668985
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554585A Pending JP2019515908A (ja) | 2016-04-20 | 2017-04-20 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2021140920A Pending JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2023179367A Pending JP2024020212A (ja) | 2016-04-20 | 2023-10-18 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
| JP2025134679A Pending JP2025163273A (ja) | 2016-04-20 | 2025-08-13 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021140920A Pending JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2023179367A Pending JP2024020212A (ja) | 2016-04-20 | 2023-10-18 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
| JP2025134679A Pending JP2025163273A (ja) | 2016-04-20 | 2025-08-13 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190224220A1 (enExample) |
| EP (2) | EP4295909A3 (enExample) |
| JP (4) | JP2019515908A (enExample) |
| WO (1) | WO2017184871A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| AR113908A1 (es) | 2017-11-24 | 2020-06-24 | H Lundbeck As | Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson |
| EP3880210A1 (en) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| WO2020115753A1 (en) * | 2018-12-05 | 2020-06-11 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | L-dopa and/or dopa decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US12391650B2 (en) | 2019-05-21 | 2025-08-19 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| CN113677675B (zh) | 2019-05-21 | 2024-07-26 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| CN113727979B (zh) | 2019-05-21 | 2024-09-20 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| EP3972600B1 (en) | 2019-05-21 | 2026-02-18 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| JP2024010252A (ja) | 2021-03-10 | 2024-01-24 | 田辺三菱製薬株式会社 | パーキンソン病治療のための組合せ医薬 |
| TW202428256A (zh) * | 2022-11-14 | 2024-07-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 左旋多巴的前藥 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2070994T3 (es) * | 1989-04-20 | 1995-06-16 | Zambon Spa | Profarmaco de dopamina. |
| GB9102812D0 (en) * | 1991-02-11 | 1991-03-27 | Enzymatix Ltd | Compounds |
| IT1255471B (it) * | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| US20050203061A1 (en) * | 2002-06-20 | 2005-09-15 | Shinya Yamashita | Prodrug, medicinal utilization thereof and process for producing the same |
| AU2003293423A1 (en) * | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| CA2536175C (en) * | 2003-08-29 | 2013-05-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| JP2007509973A (ja) * | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | 増強された吸収のための組成物および投与形態物 |
| JP4781352B2 (ja) * | 2004-06-04 | 2011-09-28 | ゼノポート，インコーポレーテッド | レボドパプロドラッグおよびその組成物ならびにその使用 |
| ES2402552T3 (es) * | 2004-07-06 | 2013-05-06 | Abbott Laboratories | Profármacos de inhibidores de proteasa de VIH |
| US7709527B2 (en) * | 2006-12-21 | 2010-05-04 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use |
| CA2724877C (en) * | 2008-05-20 | 2016-09-13 | Neurogesx, Inc. | Water-soluble acetaminophen analogs |
| SI2640358T1 (en) * | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| RU2021103000A (ru) * | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
-
2017
- 2017-04-20 JP JP2018554585A patent/JP2019515908A/ja active Pending
- 2017-04-20 EP EP23192663.5A patent/EP4295909A3/en active Pending
- 2017-04-20 EP EP17721269.3A patent/EP3445346A1/en not_active Withdrawn
- 2017-04-20 WO PCT/US2017/028646 patent/WO2017184871A1/en not_active Ceased
- 2017-04-20 US US16/164,073 patent/US20190224220A1/en not_active Abandoned
-
2021
- 2021-08-31 JP JP2021140920A patent/JP2022000428A/ja active Pending
-
2023
- 2023-10-18 JP JP2023179367A patent/JP2024020212A/ja active Pending
-
2025
- 2025-08-13 JP JP2025134679A patent/JP2025163273A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515908A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2020189864A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2016517888A5 (enExample) | ||
| JP2007529421A5 (enExample) | ||
| US20230128449A1 (en) | Silicate containing compositions and methods of treatment | |
| JP2013545730A5 (enExample) | ||
| JP2014516942A5 (enExample) | ||
| JP2017527532A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2013508279A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2016539156A5 (enExample) | ||
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP2011225596A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2011528333A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2013518036A5 (enExample) | ||
| JP2015522033A5 (enExample) | ||
| JP2017532316A5 (enExample) |